search
Back to results

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis (Escape)

Primary Purpose

Scalp Seborrheic Dermatitis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
clobetasol propionate shampoo (2/week)
ketoconazole shampoo (2/week)
Sponsored by
Galderma R&D
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scalp Seborrheic Dermatitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects with moderate to severe scalp Seborrheic Dermatitis

Exclusion Criteria:

  • Subjects suffering from psoriasis,
  • Subjects with a known allergy to one of the components of the test products,
  • Female subjects who are pregnant, nursing or planning a pregnancy during the study

Sites / Locations

  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center
  • Galderma Investigational Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

C propionate 4/week + Ketoconasole 2/week

C propionate 2/week + Ketoconasole 2/week

C propionate 2/week

Ketoconazole 2/week

Arm Description

Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)

Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)

Clobetasol propionate shampoo 0.05% (2/week)

Ketoconazole shampoo 2% (2/week)

Outcomes

Primary Outcome Measures

Total Severity Score (TSS): Percent Change From Baseline at Week 4
Total Severity Score (TSS) is sum of erythema, scaling and pruritus severity scores of the lesions evaluated each on a 4-point scale from 0 = None to 3 = Severe by the investigator. So minimum TSS can be 0 and maximum 9.

Secondary Outcome Measures

Full Information

First Posted
March 15, 2009
Last Updated
February 16, 2021
Sponsor
Galderma R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT00862654
Brief Title
Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Acronym
Escape
Official Title
Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Galderma R&D

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in the treatment of scalp Seborrheic Dermatitis.
Detailed Description
The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in association with an antifungal shampoo (Ketoconazole 2%) in the treatment of moderate to severe scalp Seborrheic Dermatitis compared to the antifungal shampoo alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scalp Seborrheic Dermatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
326 (Actual)

8. Arms, Groups, and Interventions

Arm Title
C propionate 4/week + Ketoconasole 2/week
Arm Type
Experimental
Arm Description
Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
Arm Title
C propionate 2/week + Ketoconasole 2/week
Arm Type
Experimental
Arm Description
Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
Arm Title
C propionate 2/week
Arm Type
Experimental
Arm Description
Clobetasol propionate shampoo 0.05% (2/week)
Arm Title
Ketoconazole 2/week
Arm Type
Active Comparator
Arm Description
Ketoconazole shampoo 2% (2/week)
Intervention Type
Drug
Intervention Name(s)
clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Intervention Description
Association: clobetasol propionate shampoo & ketoconazole shampoo
Intervention Type
Drug
Intervention Name(s)
clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Intervention Description
Association: clobetasol propionate shampoo & ketoconazole shampoo
Intervention Type
Drug
Intervention Name(s)
clobetasol propionate shampoo (2/week)
Intervention Description
Monotherapy with clobetasol propionate shampoo
Intervention Type
Drug
Intervention Name(s)
ketoconazole shampoo (2/week)
Intervention Description
Monotherpay ketoconazole shampoo (2/week)
Primary Outcome Measure Information:
Title
Total Severity Score (TSS): Percent Change From Baseline at Week 4
Description
Total Severity Score (TSS) is sum of erythema, scaling and pruritus severity scores of the lesions evaluated each on a 4-point scale from 0 = None to 3 = Severe by the investigator. So minimum TSS can be 0 and maximum 9.
Time Frame
baseline and week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with moderate to severe scalp Seborrheic Dermatitis Exclusion Criteria: Subjects suffering from psoriasis, Subjects with a known allergy to one of the components of the test products, Female subjects who are pregnant, nursing or planning a pregnancy during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Paul Ortonne, MD
Organizational Affiliation
Nice Hospital (France)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Galderma Investigational Center
City
Brugge
Country
Belgium
Facility Name
Galderma Investigational Center
City
Bruxelles
Country
Belgium
Facility Name
Galderma Investigational Center
City
Geel
Country
Belgium
Facility Name
Galderma Investigational Center
City
Gent
Country
Belgium
Facility Name
Galderma Investigational Center
City
Liege
Country
Belgium
Facility Name
Galderma Investigational Center
City
Mons
Country
Belgium
Facility Name
Galderma Investigational Center
City
Paris
Country
France
Facility Name
Galderma Investigational Center
City
Berlin
Country
Germany
Facility Name
Galderma Investigational Center
City
Bonn
Country
Germany
Facility Name
Galderma Investigational Center
City
Hamburg
Country
Germany
Facility Name
Galderma Investigational Center
City
Lubeck
Country
Germany
Facility Name
Galderma Investigational Center
City
Mahlow
Country
Germany
Facility Name
Galderma Investigational Center
City
Wuppertal
Country
Germany
Facility Name
Galderma Investigational Center
City
Seoul
Country
Korea, Republic of
Facility Name
Galderma Investigational Center
City
Guadalajara
Country
Mexico
Facility Name
Galderma Investigational Center
City
Mexico
Country
Mexico
Facility Name
Galderma Investigational Center
City
Naucalpan
Country
Mexico
Facility Name
Galderma Investigational Center
City
Zapopan, Jalisco
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
21707573
Citation
Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Br J Dermatol. 2011 Jul;165(1):171-6. doi: 10.1111/j.1365-2133.2011.10269.x.
Results Reference
derived
Links:
URL
http://www.galderma.com
Description
Sponsor general information

Learn more about this trial

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

We'll reach out to this number within 24 hrs